SCA
ALXN

Snowden Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Snowden Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,492
Closed -$233K – 823
2020
Q4 		$233K Buy
+1,492
New +$192K 0.02% 592
2019
Q3 		– Sell
-1,820
Closed -$238K – 542
2019
Q2 		$238K Buy
+1,820
New +$235K 0.02% 455
2016
Q2 		– Sell
-7,909
Closed -$1.1M – 296
2016
Q1 		$1.1M Buy
+7,909
New +$1.16M 0.38% 96

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Snowden Capital Advisors's ALXN Position: Q1 2021 in Review

Snowden Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 1,492 shares — an estimated $233K sold.

Snowden Capital Advisors first reported a position in ALXN in Q1 2016 and held it in 3 quarters. The position peaked at $1.1M in Q1 2016. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Snowden Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Snowden Capital Advisors sold 1,492 Alexion Pharmaceuticals shares in Q1 2021, an estimated $233K.
  • Snowden Capital Advisors first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Snowden Capital Advisors's Alexion Pharmaceuticals position peaked at $1.1M in Q1 2016.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Snowden Capital Advisors's 13F filing for Q1 2021, filed 8 Jan 2024.